Drugs / BR5402C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06821945 | May 2025 → May 2027 expected | schizophrenia | Boryung Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR5402C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06821945 ↗ |